

HE Mr David Sergeenko
The Minister of Labour, Health and Social Affairs
Ministry of Labour, Health and Social Affairs
144, Ak. Tsereteli Ave.
0119 Tbilisi
Georgia

12 May 2017

Decision Letter: New vaccine support – Human Papillomavirus (HPV)

Your Excellency,

I am writing in relation to Georgia's application for New Vaccines Support (NVS) for Human Papillomavirus Demonstration (HPV Demo) Programme, submitted to the Gavi Secretariat in September 2016, and the response to the clarifications requested by the Independent Review Committee (IRC), which Georgia submitted in January 2017.

The clarifications were found to be satisfactory and based on the recommendations made by the IRC, Gavi, the Vaccine Alliance has **approved** the Human Papillomavirus Vaccine proposal subject to a several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Georgia - Support for Human Papillomavirus Demonstration Programme
Appendix B: Georgia - Support for Injection Safety Devices

Please do not hesitate to contact my colleague Ms Jamilya Sherova, Senior Country Manager for Georgia, at jsherova@gavi.org if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
 The EPI Manager
 WHO Country Representative
 UNICEF Country Representative
 WHO Regional Office
 UNICEF Regional Office
 WHO HQ
 UNICEF Programme Division
 UNICEF Supply Division

Decision Letter – Georgia - Support for Human Papillomavirus Vaccine (HPV) Demonstration Programme

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Georgia			
2. Vaccines grant number: 1718-GEO-19b-X Cash support grant number: 1718-GEO-24a-Y			
3. Date of Decision Letter: 12/05/2017			
4. Date of the Partnership Framework Agreement: 26/02/2016			
5. Programme title: Human Papiloma Virus Demonstration Programme			
6. Vaccine type: Human Papiloma Virus (HPV)			
7. Preferred product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID			
8. Programme duration¹: 2017 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable):			
	2017	2018	Total²
HPV vaccines (US\$)	132,000	145,500	277,500
Cash (\$)	147,000	25,000	172,000
Total programme Budget (US\$)	279,000	170,500	449,500
10. Vaccine introduction grant: Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³ <i>Vaccines:</i>			
Type of supplies to be purchased with Gavi funds in each year	2017	2018	
Number of HPV vaccines doses	28,700	31,700	
Annual Amounts (US\$)	132,000	145,500	
<i>Cash support:</i>			
Cash support by year	2017		
Annual Amounts (US\$)	147,000		
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			
15. Operational support for campaigns: Not applicable			
16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions for the approval of the US\$25,000. Further details can be found in the HPV application guidelines.			
Reports, documents and other deliverables	Due dates		
1. A copy of the approval by the local ethics committee, <i>if a country determined that review and approval was required.</i>	As soon as they become available, and at the latest by end of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)		


¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

2. Three evaluation reports of the HPV vaccination demonstration programme: a. Post Introduction Evaluation (PIE) b. Coverage survey c. Costing analysis 3. A report of the assessment of adolescent health interventions, with conclusions about what interventions would be feasible for integration in year 2. a. If an adolescent health intervention is identified for joint delivery with HPV vaccine, the report should describe the identified intervention, the modified plans for Year 2, and the steps required for implementation with the district(s) and staff involved. b. If NO adolescent health intervention is identified for joint delivery with HPV vaccine the report should mention the reason why not. 4. A summary of the activities completed and progress towards the development of a national cervical cancer prevention and control strategy.	
5. A financial and activity report of expenditures by the end of year 1.	End of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)
6. If an adolescent health intervention is identified for joint delivery with HPV vaccine OR if the country substantially changed their delivery strategy: a. A new survey to measure the coverage of HPV vaccination and the coverage of the jointly delivered health intervention(s) and b. An updated micro-costing analysis of programme delivery costs. (Annex B) 7. If NO adolescent health intervention is identified for joint delivery with HPV vaccine in Year 2: A summary report of year 2 delivery of HPV vaccinations 8. A financial and activity report of expenditures in year 2. 9. A copy of the developed or revised national cervical cancer prevention and control strategy.	End of Year 2 (the second year starts when the first dose of vaccine is administered to a new cohort, which is usually 12 months after the start of Year 1 and continues for twelve calendar months)
17. Financial clarifications: Not applicable	
18. Other conditions: Not applicable	

Signed by



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 May 2017

Decision Letter – Georgia - Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Georgia			
2. Grant number: 17-GEO-32a-X; 18-GEO-32a-X			
3. Date of Decision Letter: 12/05/2017			
4. Date of the Partnership Framework Agreement: 26/02/2016			
5. Programme title: Injection Safety Devices ⁴			
6. Programme duration⁵: 2017 - 2018			
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2017	2018	Total⁶
Programme Budget (US\$)	4,000	2,000	6,000
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁷			
TOTAL injection safety devices to be purchased with Gavi funds in each year		2017	2018
Number of AD syringes		67,000	33,200
Number of safety boxes		775	375
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)		4,000	2,000
injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u>			
New Vaccine Support (NVS), Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID,Routine		2017	2018
Number of AD syringes		36,800	
Number of safety boxes		425	
Annual Amounts for injection safety devices for Vaccine (US\$)		2,000	
New Vaccine Support (NVS), HPV Quadrivalent, 1 dose(s) per vial, LIQUID,Demonstration		2017	2018
Number of AD syringes		30,200	33,200
Number of safety boxes		350	375
Annual Amounts for injection safety devices for Vaccine (US\$)		2,000	2,000

⁴ This does not include vaccines.

⁵ This is the entire duration of the Programme.

⁶ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁷ This is the amount that Gavi has approved.

9. Procurement agency: UNICEF
10. Self-procurement: Not applicable
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by

Hind K. Khatib

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 May 2017